Stratos Wealth Partners LTD. Purchases Shares of 4,365 Mazor Robotics Ltd. (MZOR)
Stratos Wealth Partners LTD. purchased a new stake in Mazor Robotics Ltd. (NASDAQ:MZOR) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,365 shares of the medical instruments supplier’s stock, valued at approximately $216,000.
Other large investors have also bought and sold shares of the company. Quantbot Technologies LP purchased a new stake in Mazor Robotics in the second quarter valued at $135,000. Advisor Group Inc. boosted its stake in shares of Mazor Robotics by 365.8% during the 3rd quarter. Advisor Group Inc. now owns 2,795 shares of the medical instruments supplier’s stock worth $138,000 after acquiring an additional 2,195 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Mazor Robotics by 398.5% during the 1st quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock worth $208,000 after acquiring an additional 5,579 shares in the last quarter. Halbert Hargrove Russell LLC purchased a new stake in shares of Mazor Robotics during the 3rd quarter worth about $214,000. Finally, BB&T Securities LLC purchased a new stake in shares of Mazor Robotics during the 2nd quarter worth about $248,000. 26.61% of the stock is currently owned by institutional investors.
Several equities research analysts have recently issued reports on MZOR shares. Ladenburg Thalmann Financial Services set a $54.00 target price on shares of Mazor Robotics and gave the stock a “buy” rating in a research note on Wednesday, August 30th. Needham & Company LLC reissued a “hold” rating on shares of Mazor Robotics in a research note on Wednesday, August 30th. Zacks Investment Research lowered shares of Mazor Robotics from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. TheStreet raised shares of Mazor Robotics from a “d” rating to a “c-” rating in a research note on Wednesday, November 8th. Finally, Barclays PLC reissued a “hold” rating and set a $34.00 target price on shares of Mazor Robotics in a research note on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company’s stock. Mazor Robotics currently has a consensus rating of “Hold” and a consensus target price of $39.83.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Stock Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related stocks with our FREE daily email newsletter.